Neem Biotech is responding to the current global antimicrobial resistance crisis by development of a novel approach to managing bacterial virulence. This approach could potentially be used as an adjunctive intervention in the treatment of infectious diseases.
It is widely recognised that compounds derived from natural origins can possess powerful and wide-ranging, albeit not well evidenced, medicinal properties. Neem has extensive experience in producing organosulphur-derived compounds that are known for their antimicrobial activities. This legacy expertise in organosulphur chemistry has allowed us to identify a number of synthetic compounds with high antimicrobial activity.
Such compounds are based on complex chemistry and chemistry/ biology interactions that are not yet well understood by experts. This can present unique challenges for conventionally accepted current pharmaceutical drug development processes. Organosulphur compounds are no exception.
Working with such compounds in drug development requires scientific rigour and an element of innovation in analytical methods to achieve credible results for the compound under development in the most cost-effective manner.
The current collaboration with LGC therefore aims to develop and validate an innovative and reliable analytical method to measure our novel target compound in biological matrices.
The validated method can then be used in subsequent preclinical studies with this and other organosulphur compound assets that may be generated.
This joint innovation by LGC and Neem Biotech could have potential to be game-changing more broadly for the state-of-the-art of natural compound analytics.